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Aspergillus PCR testing of serum provides technical simplicity but with potentially reduced sensitivity compared to whole-blood
testing. With diseases for which screening to exclude disease represents an optimal strategy, sensitivity is paramount. The associ-
ated analytical study confirmed that DNA concentrations were greater in plasma than those in serum. The aim of the current
investigation was to confirm analytical findings by comparing the performance of Aspergillus PCR testing of plasma and serum
in the clinical setting. Standardized Aspergillus PCR was performed on plasma and serum samples concurrently obtained from
hematology patients in a multicenter retrospective anonymous case-control study, with cases diagnosed according to European
Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of
Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus definitions (19 proven/probable cases and 42
controls). Clinical performance and clinical utility (time to positivity) were calculated for both kinds of samples. The sensitivity
and specificity for Aspergillus PCR when testing serumwere 68.4% and 76.2%, respectively, and for plasma, they were 94.7% and
83.3%, respectively. Eighty-five percent of serum and plasma PCR results were concordant. On average, plasma PCR was positive
16.8 days before diagnosis and was the earliest indicator of infection in 13 cases, combined with other biomarkers in five cases.
On average, serum PCRwas positive 10.8 days before diagnosis and was the earliest indicator of infection in six cases, combined
with other biomarkers in three cases. These results confirm the analytical finding that the sensitivity of Aspergillus PCR using
plasma is superior to that using serum. PCR positivity occurs earlier when testing plasma and provides sufficient sensitivity for
the screening of invasive aspergillosis while maintaining methodological simplicity.
Attempts to standardize PCR to aid in the diagnosis of invasiveaspergillosis (IA) have provided an optimal methodology for
the testing of serum and whole blood (WB) (1, 2). A multicenter
comparison of the clinical performance of PCR showed a trend
toward improved sensitivity (85% versus 79%) and earlier posi-
tivity when testing WB compared to serum (3). Even in very high-
risk patient groups, the incidence of IA rarely exceeds 15%, and
diagnostic tests are best used as a screening tool to exclude disease,
reducing the need for empirical antifungal therapy through their
excellent negative predictive value (4–6). Any reduction in sensi-
tivity, albeit even if statistically insignificant, might result in an
increase in false-negative results, a lack of confidence in the assay,
and continued reliance on empirical therapy.
Testing plasma may improve sensitivity compared to PCR de-
tection of Aspergillus DNA in serum. A study comparing the per-
formance of a galactomannan (GM)-enzyme immunoassay (EIA)
in serum and plasma showed that the mean index generated by
testing plasma was significantly greater than that for serum (0.315
versus 0.279, respectively; P 0.0398), and more cases were diag-
nosed (7). It was proposed that the blood clot had reduced the
available GM within serum samples. In an animal model study
evaluatingAspergillusPCR testing on different blood fractions, the
clot was found to contain the greatest concentration of Aspergillus
DNA (8). Testing the clot material in routine clinical diagnostics is
feasible but has practical limitations. A solution is to simply avoid
clot formation by testing plasma.
The accompanying paper (9) describes a multicenter analytical
evaluation of Aspergillus PCR testing of serum and plasma that
confirmed this difference in performance. When whole blood was
spiked with clinically expected quantities of A. fumigatus genomic
DNA and subsequently fractionated into serum and plasma, it was
found that positivity, as determined by Aspergillus PCR crossing
points (quantification cycle [Cq]) were significantly earlier for
plasma compared to those for serum, indicating that there was a
greater fungal burden available in plasma than in serum, as PCR
efficiency appeared to be comparable for the two samples (9).
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To further investigate the difference in available Aspergillus
DNA load in serum and plasma, a retrospective case-control study
was undertaken in two centers using DNA extraction and Asper-
gillus PCR methodology, in accordance with the recent European
Aspergillus PCR Initiative (EAPCRI) recommendations (2).
MATERIALS AND METHODS
Study design and patient population. The clinical evaluation was per-
formed over 12 months by two centers experienced in Aspergillus PCR
testing based in Public Health Wales, Microbiology Cardiff (PHW), Car-
diff, United Kingdom, and the University of Würzburg (UKW), Würz-
burg, Germany. Initially, EDTA whole-blood and clotted-blood samples
were concurrently sent at the request of a consulting clinician for routine
Aspergillus PCR and GM-EIA diagnostic investigations as part of local
screening strategies. On completion of routine testing, excess plasma and
serum were stored at80°C for quality control and performance assess-
ment purposes. Retrospective testing on excess serum and plasma was
performed as an anonymous case-control study to assess the performance
of Aspergillus PCR assays, and it did not impact patient management. All
clinical information was gathered as part of routine diagnostic care, and
no further information specific to this study was required. The study was
approved by local ethical and research and development boards.
Cases were selected on the basis of a diagnosis of proven/probable IA,
categorized using the revised European Organization for Research and
Treatment of Cancer/Invasive Fungal Infections Cooperative Group and
the National Institute of Allergy and Infectious Diseases Mycoses Study
Group (EORTC-MSG) definitions, relying on GM-EIA as the mycological
criterion for defining probable cases (10). The PCR result was not used in
defining disease. Cases of probable IA in each center were confirmed by
the other center reviewing the radiological evidence. Controls were se-
lected on the basis of risk factors, but possible IA cases were not included
in the study, due to diagnostic ambiguity. The baseline patient demo-
graphics are shown in Table 1.
Galactomannan EIA. GM-EIA testing was performed using the Plate-
lia Aspergillus EIA (Bio-Rad), according to the manufacturer’s instruc-
tions, and all runs were required to meet the designated validity criteria.
The GM-EIA was considered positive when the optical density was0.5.
DNA extraction. All manual DNA extraction steps were performed in
a class 2 laminar flow cabinet and were compliant with EAPCRI recom-
mendations (2). At PHW, DNA was extracted from 0.5 ml of undiluted
serum and plasma using the commercially available DSP virus kit on the
Qiagen EZ1 XL Advance automated extractor, according to the manufac-
turer’s instructions, and DNA was eluted in 60 l. At UKW, DNA was
extracted from 1.0 ml of undiluted serum and plasma using the commer-
cially available Qiagen UltraSens virus kit, according to the manufactur-
er’s instructions, with the following modifications: (i) no carrier RNA was
used, (ii) lysate centrifugation was adjusted to 3,000  g, and (iii) the
elution buffer volume was increased to 70 l and was incubated on
the column at room temperature for 2 min, followed by centrifugation of
the tubes for 2 min (3). At PHW, extractions included a positive control
(serum/plasma spiked with 20 genome equivalents [ge] of A. fumigatus
DNA) and a negative control (serum/plasma from a healthy donor), while
at UKW, only a negative control was utilized.
PCR amplification. The PCR methods showed comparable perfor-
mance when testing EAPRCI panels and were conducted in accordance
with the EAPCRI recommendations, including the use of an internal con-
trol PCR to monitor inhibition (1, 2).
At UKW, an Aspergillus-specific real-time PCR assay targeting the in-
ternal transcribed spacer 1 (ITS1)/5.8S rRNA gene region was used as
previously described (3). The final reaction volume was 21l, containing
0.3 M forward primer, 0.3 M reverse primer, 0.15 M hydrolysis
probe, 10 l of TaqMan gene expression master mix (Applied Biosys-
tems), and 10 l of template DNA. Amplification was performed using a
StepOnePlus machine (Applied Biosystems), with the following condi-
tions: 95°C for 10 min, and 60 cycles of 95°C for 5 s, 54°C for 15 s, and 72°C
for 1 s. Negative and positive PCR controls were included for every run.
At PHW, the Aspergillus real-time PCR test was performed as a single-
round assay using a Rotor-Gene Q high-resolution melting (HRM) in-
strument (Qiagen, United Kingdom) targeting the 28S rRNA gene, as
previously described (11). The final reaction volume was 50l, containing
0.75 M primers, 0.4 M hydrolysis probe, 4 mM MgCl2, 5 l of Roche
LightCycler hybridization master mix (Roche, United Kingdom), 9 l of
molecular-grade water, and 15 l of template DNA. PCR controls in the
form of cloned PCR products (300, 30, and 3 input copies) and no-tem-
plate molecular-grade water were included to monitor PCR performance.
Both centers tested each sample in duplicate. The analytical threshold
was defined by at least one replicate generating a positive signal at any
cycle during the PCR.
Statistical analysis. Patients with proven and probable IA were clas-
sified as cases, and patients with no evidence of fungal disease were cate-
gorized as controls. The clinical performance was defined using both sin-
gle-positive PCR and multiple-positive (2) PCR thresholds. The validity
of positive PCR was determined by comparing the rate of positivity in
samples originating from cases compared to the rate of false positivity in
control samples. Sensitivity, specificity, positive and negative likelihood
ratios, and the diagnostic odds ratios of the PCR assays were calculated
using 2 by 2 tables. Predictive values were not calculated because of the
artificially high prevalence of IA (proven/probable IA, 19/62 [30.6%]),
which is typical of case-control studies. Ninety-five percent confidence
intervals were generated for each proportionate value and, where re-
quired, P values (Fisher’s exact test; significance threshold, P 0.05) were
calculated to determine the significance of the difference between rates
(12). A Kappa statistic was calculated to test the agreement between PCR
results and was applied individually to the total population and for cases
and controls. The observed agreement between PCR results and between
PCR and GM-EIA results was also calculated. For cases of IA, the first
assay result from serum PCR, plasma PCR, and GM-EIA to become pos-
itive was identified, and the timing of PCR positivity was compared to that
of a diagnosis of IA, as determined by the date at which histology or both
radiology and GM-EIA were positive.
Cq values for PCR-positive results and for cases and controls were also
compared, with both Cq values being included for the confirmed positive
results. The Kolmogorov-Smirnov test, D’Agostino-Pearson test, and
Shapiro-Wilk test were applied to all populations to determine normality.
TABLE 1 Patient demographics with EORTC-MSG diagnosis of IAa
Demographicb
Proven/probable IA
(n 19) NEF (n 42)c
No. of males/no. of females 13/6 25/17
Age (mean [range]) (yr) 52.2 (24–73) 52.5 (21–78)
Underlying condition (no.)
AML/MDS 12 22
Lymphoma 4 5
Myeloma 6
ALL 1 2
AA 1 1
CML/CLL 1 4
Other 2d
IPA (no.) 15 None
IPA/sinusitis (no.) 4
a IA, invasive aspergillosis.
b AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; ALL, acute
lymphoblastic leukemia; AA, aplastic anemia; CLL, chronic lymphoblastic leukemia;
CML, chronic myeloid leukemia; IPA, invasive pulmonary aspergillosis. Lymphoma
comprises Hodgkin, non-Hodgkin lymphoma and diffuse large B-cell lymphoma.
c NEF, no evidence of fungal disease (control population).
d Includes one case of myelofibrosis and one case of combined immunodeficiency with
lymphoproliferation.
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To overcome differences in the population distribution, the significance
of differences in serum-positive PCR results in cases and controls were
compared using an unpaired Student t test, whereas the significance of
differences between plasma-positive PCR results in cases and controls
were compared using a Mann-Whitney test. For both investigations, sig-
nificance was defined by aP value of 0.05 using a two-tailed test. A receiver
operating characteristic (ROC) curve was generated using the earliest Cq
value generated per patient to determine whether a particular Cq thresh-
old provided optimal PCR performance when testing both serum and
plasma. For this analysis, in patients negative by PCR, a Cq value of 50
cycles was applied, representing the lowest number of PCR cycles per-
formed.
RESULTS
Sample population. One case of proven IA, 18 episodes (17 cases,
as one patient had two episodes 1 year apart and was considered to
have clinically improved between episodes) of probable IA, and 42
patients with no evidence of invasive fungal disease formed the
controls. A total of 393 paired serum and plasma samples were
tested. One hundred ninety samples (median per patient, 10 sam-
ples [range, 3 to 25 samples]; median sampling period, 58 days
[range, 6 to 119 days]) originated from proven/probable cases of
IA, and samples prior to and after diagnosis were included to
determine any differences in sample type performance. Two hun-
dred three samples were from control patients (median per pa-
tient, 4 [range, 3 to 9]; median sampling period, 31 days [range, 7
to 297]) and were temporally interspersed between the episodes of
proven/probable IA. Although the median sampling period for
the controls was less than that for the cases, it represented the
typical period of time in which multiple-PCR-positive results
were encountered with respect to a clinical diagnosis (median, 24
days; range, 6 to 80 days).
Sample positivity rates. The overall positivity rates for PCR
testing of plasma and serum were 53/393 (13.5%; 95% confidence
interval [CI], 10.5 to 17.2%) and 48/393 (12.2%; 95% CI, 9.3 to
15.8%), respectively, and were not significantly different (P 
0.7483). The true-positive rates in cases were significantly higher
than the false-positive rates in the control population for both
sample types (P  0.0001), indicating that PCR positivity was
associated with IA. For plasma PCR, the positivity rate in cases was
46/190 (24.2%; 95% CI, 18.7 to 30.8%) compared to 7/203 (3.4%;
95% CI, 1.7 to 7.0%) in the control population. Serum PCR pos-
itivity in cases was 36/190 (18.9%; 95% CI, 14.0 to 25.1%) com-
pared to a false-positive rate of 12/203 (5.9%; 95% CI, 3.4 to
10.1%). There was no significant difference between plasma and
serum PCR positivity rates when testing samples originating from
cases (P 0.2617) or controls (P 0.3476).
Sample concordance. The observed sample agreement be-
tween PCR testing of serum and plasma for the total population
was 85.5% (95% CI, 80.4 to 89.5%), generating a Kappa statistic of
0.353, which represents fair agreement (Table 2). For the samples
originating from cases, 152/190 (80.0%; 95% CI, 71.6 to 86.5%; 22
PCR positive and 130 PCR negative) were concordant in plasma
and serum, and 38/190 (24 plasma PCR positive/serum PCR neg-
ative and 14 plasma PCR negative/serum PCR positive) were con-
flicting, yielding a Kappa of 0.411, which represents moderate
agreement. For the samples originating from the controls, 184/203
(90.6%; 95% CI, 85.9 to 93.9%) that were negative by both plasma
and serum PCR and 19 (7 plasma PCR positive/serum PCR neg-
ative and 12 plasma PCR negative/serum PCR positive) gave con-
flicting results. It was not possible to calculate a Kappa statistic for
these.
The overall observed agreement between plasma PCR and
GM-EIA testing and serum PCR between and GM-EIA was 85.0%
(95% CI, 79.8 to 89.1%) and 84.0% (95% CI, 78.7 to 88.2%),
respectively, yielding Kappa statistics of 0.232 and 0.307, which
indicate poor and fair agreement, respectively (Table 3).
Comparisonof crossing point (Cq) values.For plasma,Cq val-
ues for positive samples occurred significantly earlier for cases
(mean, 40.8 cycles; 95% CI, 40.1 to 41.5 cycles) than for controls
(mean, 44.5 cycles; 95% CI, 43.0 to 45.9 cycles) (Mann-Whitney
test, P 0.0005). There was no difference in a comparison of Cq
values for PCR-positive serum samples originating from cases
(mean, 40.9 cycles; 95% CI, 40.3 to 41.5 cycles) or controls (mean,
41.1 cycles; 95% CI, 40.2 to 42.1 cycles) (unpaired t test P 
0.7478) (Fig. 1). Cq values for false-positive plasma PCR results
originating from the control population occurred significantly
later than those for false-positive serum PCR results (Mann-Whit-
ney test, P 0.0009). There was no difference in Cq values in the
plasma or serum PCR-positive results of cases of IA (Mann-Whit-
ney test, P 0.2925).
For plasma, a threshold of 42.3 cycles appeared to be optimal,
generating sensitivity and specificity values of 79.0% (95% CI,
54.4 to 94.0%) and 100% (95% CI, 91.6 to 100%), respectively
(Fig. 2). A positivity threshold of 45 cycles provides sufficient sen-
sitivity to exclude IA when testing plasma, resulting in a sensitivity
of 94.7% and a negative likelihood ratio of 0.06. As the Cq values
generated by serum PCR were similar for cases and controls, it was
not possible to determine an optimal Cq threshold using ROC
analysis (Fig. 2), and a determination of the performance was
better achieved by qualitative interpretation of results (positive/
negative) (Table 4). The area under the ROC curve was signifi-
TABLE 2 Sample concordance when testing serum and plasma
specimens by Aspergillus PCR
Plasma PCR results by sample
group (no.)
No. of samples with serum PCR
result of:
Positive Negative
All samples (n 393)
Positive 22 31
Negative 26 314
IA cases (n 190)
Positive 22 24
Negative 14 130
NEF patients (n 203)
Positive 0 7
Negative 12 184
TABLE 3 Sample concordance between serum or plasma PCR and GM-
EIA
No. of PCR results of (n 393):
No. with GM-EIA result of:
Positive Negative
Serum positive 15 33
Serum negative 30 315
Plasma positive 19 33
Plasma negative 26 315
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cantly greater for plasma (area under the concentration-time
curve [AUC], 0.9555; 95% CI, 0.8889 to 1.0000) than that for
serum PCR (AUC, 0.7318; 95% CI, 0.5886 to 0.8751).
Clinical performance. The clinical performance characteris-
tics for PCR when testing plasma and serum are shown in Table 4.
There was a trend toward increasing sensitivity when testing
plasma (94.7%) compared to serum (68.4%). Using a clinical
threshold of a single-PCR-positive result provided optimal sensi-
tivity but at the expense of specificity, and a single positive result
could not be used to accurately rule in IA in either plasma (likeli-
hood positive, 5.7) or serum (likelihood positive, 2.9). The use of
a clinical threshold of 2 positive PCR results within the same
episode improved PCR specificity when testing plasma (100%)
and serum (95.2%) and provided the best diagnostic odds ratio for
Aspergillus PCR. For cases with multiple PCR-positive results
(plasma PCR testing, 13/19; serum PCR testing, 8/19), all had2
positive results within a 3-week period of testing, but when testing
plasma, 8/13 patients had consecutive PCR-positive results com-
pared to 6/8 when testing serum. A diagnostic approach requiring
a PCR-positive result in both plasma and serum results in a sen-
sitivity and specificity of 68.4% (95% CI, 46.0 to 84.6%) and
95.2% (95% CI, 79.0 to 99.4%), respectively, but provided no
benefit over testing plasma alone using a clinical threshold of2
positive PCR results within the same episode.
On 13 occasions, plasma PCR was the earliest assay with a
positive result; it was the sole first positive assay result on eight
occasions, and it was concurrently positive in combination with
other assays on five occasions (Fig. 3). GM-EIA was the earliest
positive assay result on seven occasions, it was the sole first posi-
tive result on three occasions, and it was concurrently positive
with other assay results on four occasions (Fig. 3). Serum PCR was
the earliest positive result on six occasions; it was the sole first
positive result on three occasions, and it was concurrently positive
with other assays on three occasions. The first PCR-positive result
was, on average, 16.8 (95% CI, 3.6 to 30.0) and 10.8 (95% CI,8.5
to 30.1) days, respectively, earlier than the diagnosis of IA, when
testing plasma and serum. However, at a prevalence of 10%, a
single positive plasma or serum PCR result provides probabilities
of IA of 38.8% and 24.4%, respectively. Multiple-positive plasma
and serum PCR results improve the probability of IA to88.4%
and 49.4%, respectively. In waiting for these confirmatory results,
the mean time to positivity prior to a combined radiological/sero-
logical diagnosis is reduced to 7.3 (95% CI,5.7 to 20.3) and 4.0
(95% CI, 3.0 to 11.0) days for plasma and serum PCR, respec-
tively.
DISCUSSION
This clinical evaluation supports the analytical evidence confirm-
ing free DNA to be more abundant in plasma than in serum.
Plasma PCR sensitivity (94.7%) was higher than that of serum
PCR (68.4%), generating a negative likelihood ratio of 0.06, which
is sufficient to exclude disease in patients not receiving mold-
active prophylaxis/treatment (13). Unfortunately, it was not pos-
sible to identify whether individual patients were receiving mold-
active prophylaxis without breaking anonymity. However, the
effects of prophylaxis on decreasing the available fungal burden
and assay sensitivity would apply equally to serum and plasma.
The sensitivity of serum PCR in this current study was comparable
to that for serum in a previous study comparing whole-blood
(WB) and serum PCR performance, whereas the current plasma
PCR sensitivity was comparable to that of previous WB PCR (3).
Increasing assay stringency by using a clinical threshold of 2
PCR-positive results improved plasma PCR specificity to 100%,
with a positive likelihood ratio of68.4; this would allow IA to be
reliably diagnosed (Table 4), although it would delay the diagnosis
by a median of 14 days (range, 2 to 24 days) compared to that with
a single PCR-positive result, limiting clinical utility. Plasma was
the first indicator of IA in 68% of cases, albeit in combination with
other biomarker tests in just under half.
In the analytical study, the Cq values associated with true-pos-
itive PCR results with plasma occurred significantly earlier than
those with serum. Conversely, in the clinical study, there was no
significant difference in Cq values for true-positive results when
testing plasma or serum, although false-positive results occurred
significantly later when testing plasma, which allowed a positivity
threshold to be determined. In the analytical study, the majority of
samples (23/27) gave concordant positive results. In the clinical
study, most positive samples (53/74) were either positive in serum
or plasma, with only 21 being positive in both. A comparison of
only concordantly positive serum and plasma samples showed a
median value for plasma of 39.8 cycles, which occurred approxi-
mately 1 cycle earlier than that found for serum (medianCq, 40.5),
(P 0.4373).
FIG 1 Comparison of crossing point values for positive PCR results when
testing serum and plasma. The horizontal bar represents the median value and
the error bars the interquartile range.
FIG 2 Receiver operating characteristic (ROC) curve for Aspergillus PCR test-
ing of serum and plasma. The ROC curve was calculated using the earliest Cq
value per patient, with patients negative by PCR given a Cq value of 50 cycles.
Each point represents a Cq value.
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The limited concordance between serum and plasma PCR and
between PCR and GM-EIA likely reflects that levels of Aspergillus
DNA in the circulation are low and at the limit of detection of
real-time PCR. As a result, PCR positivity is often not reproduc-
ible, although it is still considered significant (14). Furthermore,
the samples had been stored at80°C for an average of 9 months.
Consequently, degradation of the DNA target was a possibility
(15). For serum, no prior testing had been performed, although
for plasma PCR, positives before and after Cq values were not
significantly different (P  0.097). Given that the overall sample
positivity rates were similar and the mean Cq values for cases of IA
when testing serum (40.9 cycles) and plasma (40.8 cycles) were
almost identical, the effect of storage appears to be minimal. One
caveat is that the variability of real-time PCR Cq values at this late
stage of amplification is wide, and prospective clinical comparison
is required to overcome any associated limitations.
In the clinical study, the concentration of circulatory DNA was
lower than that encountered in the analytical evaluation. The lack
of reproducibility and the variability of Cq values associated with
testing DNA at these concentrations might explain why the earlier
Cq values associated with plasma PCR analytical testing were not
as evident in the clinical study. From an analytical perspective, it is
essential that all DNA concentrations be within the reproducible
detection range, as testing outside these boundaries might gener-
ate random erroneous results leading to false conclusions. Never-
theless, clinical performance appeared to be superior in plasma, as
the sensitivity was comparable to that found for WB PCR testing
(86%; 95% CI, 73 to 93%) (16). However, automated sample pro-
cessing is simpler, being the same as that used for serum.
Targeting free circulating Aspergillus DNA (DNAemia) is tech-
nically less demanding than targeting DNA associated within the
circulating fungal cells (2). The analytical evaluation showed that
the amount of cell-free DNA is greater in plasma than that in
serum, which is likely the result of DNA becoming trapped during
clot formation (9). DNA concentrations in clot material have been
shown to be higher than those found in serum, supporting this
hypothesis (8). Moreover, the use of clots in daily practice is tech-
nically challenging. Usually, blood is drawn into 4- to 6-ml Vacu-
tainers, and subsequent clot formation will occupy approximately
half of this volume, so it cannot be processed unless it is divided
into smaller amounts. Testing a single aliquot of this divided ma-
terial would be preferable, but it assumes an equal distribution of
Aspergillus DNA within the clot. Whether this is the case has not
been determined and might result in false negativity. Testing
multiple aliquots increases costs and the complexity of inter-
pretation, as positivity may vary between aliquots. Since the use
of plasma precludes clot formation, there may be a reduction in
the loss of DNA.
In summary, testing of serum and plasma by PCR is technically
less demanding than that of WB and allows Aspergillus PCR to be
performed in routine molecular diagnostic laboratories alongside
viral and bacterial assays. This multicenter clinical evaluation sup-
ports the analytical findings in the accompanying manuscript (9),
in which analytical sensitivity in plasma appeared superior to that
of serum. In the clinical evaluation, there was a trend toward in-
creased sensitivity, and positivity occurred earlier when testing
plasma. Despite the limitations (population size and retrospective
testing) of this case-control study, the results justify further pro-
spective cohort or randomized control studies to confirm clinical
validity and accurately define the clinical utility of testing different
types of specimens.
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